Journal
EUROPEAN JOURNAL OF ENDOCRINOLOGY
Volume 166, Issue 5, Pages 861-868Publisher
BIOSCIENTIFICA LTD
DOI: 10.1530/EJE-12-0041
Keywords
-
Categories
Funding
- Medical Research Council
- British Heart Foundation
- Pfizer Ltd.
- Instituto de Salud Carlos III (Spain) [13SNS-INT 11/323]
- MRC [G0500877, G0700704] Funding Source: UKRI
- British Heart Foundation [RG/11/4/28734] Funding Source: researchfish
- Chief Scientist Office [CZB/4/582, CZG/2/478] Funding Source: researchfish
- Medical Research Council [G0700704B, G0500877, G0700704] Funding Source: researchfish
- The Sir Jules Thorn Charitable Trust [09/01PhD] Funding Source: researchfish
Ask authors/readers for more resources
Objective: Both type 2 diabetes and glucocorticoid therapy are highly prevalent. Although people with type 2 diabetes may be more susceptible to adverse effects of glucocorticoids, and it is recommended that glucocorticoid therapy is avoided for fear of worsening glycaemic control, the extent to which this advice is followed and the consequences when glucocorticoids are prescribed are poorly documented. The aim was to assess the characteristics of people with type 2 diabetes prescribed glucocorticoids in a real-world setting and to quantify resulting adverse effects. Design: Cross-sectional cohort study. Methods: Cardiometabolic variables, body fat distribution, cognitive function and mood were studied in the 1066 participants of the Edinburgh Type 2 Diabetes Study, of whom 162 (15%) were taking systemic, topical or inhaled glucocorticoids. Results: Glucocorticoid therapy was more common in women and in smokers but was not avoided in patients with diabetic complications or cardiovascular risk factors. People taking glucocorticoids were more centrally obese with slightly higher HbA1c and total serum cholesterol but were no more likely to have hepatic steatosis or hypertension. Glucocorticoid treatment was associated with substantially lower mood and greater anxiety. Women taking glucocorticoid therapy were twice as likely to report depressive symptoms compared with those not taking treatment. Glucocorticoid therapy was also associated with poorer cognitive function among those with subclinical atherosclerosis, as indicated by low ankle-brachial pressure index. Conclusions: Glucocorticoids are prescribed commonly for people with type 2 diabetes despite being associated with adverse indices of glycaemic control, cardiovascular risk factors, mood and cognitive function.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available